Eli Lilly Offering Possible 5.49% Return Over the Next 23 Calendar Days

Eli Lilly's most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $55.00 short call and a strike $60.00 long call offers a potential 5.49% return on risk over the next 23 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $55.00 by expiration. The full premium credit of $0.26 would be kept by the premium seller. The risk of $4.74 would be incurred if the stock rose above the $60.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.

The RSI indicator is at 61.78 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Eli Lilly

Amgen Readies Cholesterol Drug After Results From Trial
Thu, 30 Jan 2014 23:56:22 GMT
Bloomberg – Amgen Inc. (AMGN) said it completed a fifth late-stage study of its experimental anti-cholesterol medicine, as it leads competitors trying to bring a new class of therapies to a market estimated to be worth billions. The new treatments target a protein called PCSK9 that’s associated with high levels of LDL, or “bad,” cholesterol. Amgen’s drug, evolocumab, met the study goals, enabling the company to proceed with an application for approval this year from regulators, Thousand Oaks, California-based Amgen said today in a statement. That puts Amgen, the world’s largest biotechnology company by revenue, ahead by six months to a year of its closest competitor in the drug class, a compound being developed by Sanofi (SAN) and Regeneron Pharmaceuticals Inc. (REGN), according to Eric Schmidt , an analyst with Cowen & Co. He estimates Amgen’s drug may target as many as 17 million patients in the U.S., Europe and Japan.

[$$] Lilly Profit Drops 12%
Thu, 30 Jan 2014 23:50:05 GMT
The Wall Street Journal – Eli Lilly's fourth-quarter earnings fell 12% as the drug maker entered a new round of patent expirations that will erode sales of top drugs throughout 2014.

Sanofi sues Eli Lilly over patents for top-selling insulin drug
Thu, 30 Jan 2014 23:15:23 GMT
Reuters – French drugmaker Sanofi sued Eli Lilly and Co on Thursday, alleging that the U.S. pharmaceutical company infringed patents on its top-selling diabetes treatment, the insulin product Lantus. The lawsuit, filed in United States District Court for the District of Delaware, was triggered by notification from Lilly last month that it applied with the U.S. Food and Drug Administration (FDA) seeking permission to sell a generic version of Lantus, known chemically as insulin glargine. Lilly, in its submission, challenged the validity of several patents on Lantus held by Sanofi.

6:33 am Eli Lilly reports EPS in-line, beats on revs; reaffirms FY14 guidance
Thu, 30 Jan 2014 20:57:36 GMT
Briefing.com – 6:33 am Eli Lilly reports EPS in-line, beats on revs; reaffirms FY14 guidance

Eli Lilly Beats on Earnings & Revs, Confirms View
Thu, 30 Jan 2014 19:40:03 GMT
Zacks – 2014 will be a challenging year for Eli Lilly with two major products – Cymbalta and Evista – facing generic competition this year.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.